18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer

Simon JD Harley, Richard Hoffmann, Dylan Bartholomeusz, Peter Sutherland, Barry Chatterton, Michael Kitchener, Prab Takhar, Chris Tsopelas, Andrew Fuller, Richard Wells, Raj Singh-Rai, John Bolt

Research output: Research - peer-reviewArticle

Abstract

Background: 18-Fluoride labeled sodium fluoride (Na-18-F) positron emission tomography with computer tomography (PET/CT) has a better sensitivity and specificity than whole body bone scan (WBBS) in detecting osseous metastatic prostate cancer. We performed a pilot study of 20 men to examine what level of impact Na-18-F PET/CT has on management plans when used for staging newly diagnosed prostate cancer. Materials and methods: Twenty men were prospectively enrolled into the study in South Australia. Men were eligible if they had newly diagnosed, untreated, and biopsy-confirmed intermediate- or high-risk prostate cancer (D'Amico classification). WBBS and Na-18-F PET/CT scans were performed within 1 week of each other. Following review of the WBBS, treatment type and intent was documented by the treating urologist. The Na-18-F PET/CT scan was then reviewed. The impact of the Na-18-F PET/CT was measured on whether treatment modality or intent was subsequently altered: high impact = treatment intent or modality was changed; medium impact = treatment modality was modified; low impact = no change in treatment. Results: In 18 men (90%), the WBBS and Na-18-F PET/CT were negative for osseous metastases. In one man (5%), the WBBS demonstrated widespread osseous metastases which were similarly demonstrated on the Na-18-F PET/CT. One man (5%) had a normal WBBS; however, the Na-18-F PET/CT demonstrated widespread osseous metastases. Subsequently, in 19 men (95%), the results of the two scans were congruent and the addition of the Na-18-F PET/CT scan demonstrated a low impact on management. In one man (5%), the addition of the Na-18-F PET/CT had a high impact as treatment type and intent was altered. Conclusions: Our pilot study is the first of its kind in Australia, and our findings suggest that Na-18-F PET/CT is a safe and feasible modality for staging prostate cancer. However, its true impact on prostate cancer management warrants further investigation.

LanguageEnglish
Pages50-54
Number of pages5
JournalProstate International
Volume6
Issue number2
DOIs
StatePublished - 1 Jun 2018

Keywords

  • Metastases
  • Positron emission tomography with computer tomography
  • Prostate cancer
  • Sodium fluoride
  • Whole body bone scan

ASJC Scopus subject areas

  • Urology

Cite this

Harley, Simon JD ; Hoffmann, Richard ; Bartholomeusz, Dylan ; Sutherland, Peter ; Chatterton, Barry ; Kitchener, Michael ; Takhar, Prab ; Tsopelas, Chris ; Fuller, Andrew ; Wells, Richard ; Singh-Rai, Raj ; Bolt, John. / 18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography : the impact of pretreatment staging in intermediate- and high-risk prostate cancer. In: Prostate International. 2018 ; Vol. 6, No. 2. pp. 50-54
@article{486a9c3e637e49ed8751ca5e0ea772e6,
title = "18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer",
abstract = "Background: 18-Fluoride labeled sodium fluoride (Na-18-F) positron emission tomography with computer tomography (PET/CT) has a better sensitivity and specificity than whole body bone scan (WBBS) in detecting osseous metastatic prostate cancer. We performed a pilot study of 20 men to examine what level of impact Na-18-F PET/CT has on management plans when used for staging newly diagnosed prostate cancer. Materials and methods: Twenty men were prospectively enrolled into the study in South Australia. Men were eligible if they had newly diagnosed, untreated, and biopsy-confirmed intermediate- or high-risk prostate cancer (D'Amico classification). WBBS and Na-18-F PET/CT scans were performed within 1 week of each other. Following review of the WBBS, treatment type and intent was documented by the treating urologist. The Na-18-F PET/CT scan was then reviewed. The impact of the Na-18-F PET/CT was measured on whether treatment modality or intent was subsequently altered: high impact = treatment intent or modality was changed; medium impact = treatment modality was modified; low impact = no change in treatment. Results: In 18 men (90%), the WBBS and Na-18-F PET/CT were negative for osseous metastases. In one man (5%), the WBBS demonstrated widespread osseous metastases which were similarly demonstrated on the Na-18-F PET/CT. One man (5%) had a normal WBBS; however, the Na-18-F PET/CT demonstrated widespread osseous metastases. Subsequently, in 19 men (95%), the results of the two scans were congruent and the addition of the Na-18-F PET/CT scan demonstrated a low impact on management. In one man (5%), the addition of the Na-18-F PET/CT had a high impact as treatment type and intent was altered. Conclusions: Our pilot study is the first of its kind in Australia, and our findings suggest that Na-18-F PET/CT is a safe and feasible modality for staging prostate cancer. However, its true impact on prostate cancer management warrants further investigation.",
keywords = "Metastases, Positron emission tomography with computer tomography, Prostate cancer, Sodium fluoride, Whole body bone scan",
author = "Harley, {Simon JD} and Richard Hoffmann and Dylan Bartholomeusz and Peter Sutherland and Barry Chatterton and Michael Kitchener and Prab Takhar and Chris Tsopelas and Andrew Fuller and Richard Wells and Raj Singh-Rai and John Bolt",
year = "2018",
month = "6",
doi = "10.1016/j.prnil.2017.12.002",
volume = "6",
pages = "50--54",
journal = "Prostate International",
issn = "2287-8882",
number = "2",

}

Harley, SJD, Hoffmann, R, Bartholomeusz, D, Sutherland, P, Chatterton, B, Kitchener, M, Takhar, P, Tsopelas, C, Fuller, A, Wells, R, Singh-Rai, R & Bolt, J 2018, '18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer' Prostate International, vol 6, no. 2, pp. 50-54. DOI: 10.1016/j.prnil.2017.12.002

18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography : the impact of pretreatment staging in intermediate- and high-risk prostate cancer. / Harley, Simon JD; Hoffmann, Richard; Bartholomeusz, Dylan; Sutherland, Peter; Chatterton, Barry; Kitchener, Michael; Takhar, Prab; Tsopelas, Chris; Fuller, Andrew; Wells, Richard; Singh-Rai, Raj; Bolt, John.

In: Prostate International, Vol. 6, No. 2, 01.06.2018, p. 50-54.

Research output: Research - peer-reviewArticle

TY - JOUR

T1 - 18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography

T2 - Prostate International

AU - Harley,Simon JD

AU - Hoffmann,Richard

AU - Bartholomeusz,Dylan

AU - Sutherland,Peter

AU - Chatterton,Barry

AU - Kitchener,Michael

AU - Takhar,Prab

AU - Tsopelas,Chris

AU - Fuller,Andrew

AU - Wells,Richard

AU - Singh-Rai,Raj

AU - Bolt,John

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: 18-Fluoride labeled sodium fluoride (Na-18-F) positron emission tomography with computer tomography (PET/CT) has a better sensitivity and specificity than whole body bone scan (WBBS) in detecting osseous metastatic prostate cancer. We performed a pilot study of 20 men to examine what level of impact Na-18-F PET/CT has on management plans when used for staging newly diagnosed prostate cancer. Materials and methods: Twenty men were prospectively enrolled into the study in South Australia. Men were eligible if they had newly diagnosed, untreated, and biopsy-confirmed intermediate- or high-risk prostate cancer (D'Amico classification). WBBS and Na-18-F PET/CT scans were performed within 1 week of each other. Following review of the WBBS, treatment type and intent was documented by the treating urologist. The Na-18-F PET/CT scan was then reviewed. The impact of the Na-18-F PET/CT was measured on whether treatment modality or intent was subsequently altered: high impact = treatment intent or modality was changed; medium impact = treatment modality was modified; low impact = no change in treatment. Results: In 18 men (90%), the WBBS and Na-18-F PET/CT were negative for osseous metastases. In one man (5%), the WBBS demonstrated widespread osseous metastases which were similarly demonstrated on the Na-18-F PET/CT. One man (5%) had a normal WBBS; however, the Na-18-F PET/CT demonstrated widespread osseous metastases. Subsequently, in 19 men (95%), the results of the two scans were congruent and the addition of the Na-18-F PET/CT scan demonstrated a low impact on management. In one man (5%), the addition of the Na-18-F PET/CT had a high impact as treatment type and intent was altered. Conclusions: Our pilot study is the first of its kind in Australia, and our findings suggest that Na-18-F PET/CT is a safe and feasible modality for staging prostate cancer. However, its true impact on prostate cancer management warrants further investigation.

AB - Background: 18-Fluoride labeled sodium fluoride (Na-18-F) positron emission tomography with computer tomography (PET/CT) has a better sensitivity and specificity than whole body bone scan (WBBS) in detecting osseous metastatic prostate cancer. We performed a pilot study of 20 men to examine what level of impact Na-18-F PET/CT has on management plans when used for staging newly diagnosed prostate cancer. Materials and methods: Twenty men were prospectively enrolled into the study in South Australia. Men were eligible if they had newly diagnosed, untreated, and biopsy-confirmed intermediate- or high-risk prostate cancer (D'Amico classification). WBBS and Na-18-F PET/CT scans were performed within 1 week of each other. Following review of the WBBS, treatment type and intent was documented by the treating urologist. The Na-18-F PET/CT scan was then reviewed. The impact of the Na-18-F PET/CT was measured on whether treatment modality or intent was subsequently altered: high impact = treatment intent or modality was changed; medium impact = treatment modality was modified; low impact = no change in treatment. Results: In 18 men (90%), the WBBS and Na-18-F PET/CT were negative for osseous metastases. In one man (5%), the WBBS demonstrated widespread osseous metastases which were similarly demonstrated on the Na-18-F PET/CT. One man (5%) had a normal WBBS; however, the Na-18-F PET/CT demonstrated widespread osseous metastases. Subsequently, in 19 men (95%), the results of the two scans were congruent and the addition of the Na-18-F PET/CT scan demonstrated a low impact on management. In one man (5%), the addition of the Na-18-F PET/CT had a high impact as treatment type and intent was altered. Conclusions: Our pilot study is the first of its kind in Australia, and our findings suggest that Na-18-F PET/CT is a safe and feasible modality for staging prostate cancer. However, its true impact on prostate cancer management warrants further investigation.

KW - Metastases

KW - Positron emission tomography with computer tomography

KW - Prostate cancer

KW - Sodium fluoride

KW - Whole body bone scan

UR - http://www.scopus.com/inward/record.url?scp=85040678463&partnerID=8YFLogxK

U2 - 10.1016/j.prnil.2017.12.002

DO - 10.1016/j.prnil.2017.12.002

M3 - Article

VL - 6

SP - 50

EP - 54

JO - Prostate International

JF - Prostate International

SN - 2287-8882

IS - 2

ER -